相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Expansion of IL-23 receptor bearing TNFR2+T cells is associated with molecular resistance to anti-TNF therapy in Crohn's disease
Heike Schmitt et al.
GUT (2019)
Cell-centred meta-analysis reveals baseline predictors of anti-TNFα non-response in biopsy and blood of patients with IBD
Renaud Gaujoux et al.
GUT (2019)
OP37 Efficacy and safety of ustekinumab as maintenance therapy in ulcerative colitis: Week 44 results from UNIFI
W J Sandborn et al.
Journal of Crohns & Colitis (2019)
Low TREM1 expression in whole blood predicts anti-TNF response in inflammatory bowel disease
Bram Verstockt et al.
EBIOMEDICINE (2019)
Cytokine Networks in the Pathophysiology of Inflammatory Bowel Disease
Matthias Friedrich et al.
IMMUNITY (2019)
Group 3 ILCs: Peacekeepers or Troublemakers? What's Your Gut Telling You?!
Eirini Pantazi et al.
FRONTIERS IN IMMUNOLOGY (2019)
Effect of Fecal Microbiota Transplantation on 8-Week Remission in Patients With Ulcerative Colitis A Randomized Clinical Trial
Samuel P. Costello et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
Reversal of Intestinal Failure in Children With Tufting Enteropathy Supported With Parenteral Nutrition at Home
Iona Ashworth et al.
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION (2018)
Effector T Helper Cell Subsets in Inflammatory Bowel Diseases
Tanbeena Imam et al.
FRONTIERS IN IMMUNOLOGY (2018)
Old and New Lymphocyte Players in Inflammatory Bowel Disease
Paolo Giuffrida et al.
DIGESTIVE DISEASES AND SCIENCES (2018)
Fungal microbiota dysbiosis in IBD
Harry Sokol et al.
GUT (2017)
Efficacy and Safety of MEDI2070, an Antibody Against Interleukin 23, in Patients With Moderate to Severe Crohn's Disease: A Phase 2a Study
Bruce E. Sands et al.
GASTROENTEROLOGY (2017)
SAFETY AND EFFICACY OF ABT-494 (UPADACITINIB), AN ORAL JAK1 INHIBITOR, AS INDUCTION THERAPY IN PATIENTS WITH CROHN'S DISEASE: RESULTS FROM CELEST
William J. Sandborn et al.
GASTROENTEROLOGY (2017)
Molecular imaging of mucosal α4β7 integrin expression with the fluorescent anti-adhesion antibody vedolizumab in Crohn's disease
Timo Rath et al.
GASTROINTESTINAL ENDOSCOPY (2017)
Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials
Julian Panes et al.
GUT (2017)
Life-threatening NLRC4-associated hyperinflammation successfully treated with IL-18 inhibition
Scott W. Canna et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2017)
Faecal Microbiota Transplantation for Inflammatory Bowel Disease: A Systematic Review and Meta-analysis
Sudarshan Paramsothy et al.
JOURNAL OF CROHNS & COLITIS (2017)
Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial
Severine Vermeire et al.
LANCET (2017)
Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial
Sudarshan Paramsothy et al.
LANCET (2017)
Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study
Brian G. Feagan et al.
LANCET (2017)
Prediction of complicated disease course for children newly diagnosed with Crohn's disease: a multicentre inception cohort study
Subra Kugathasan et al.
LANCET (2017)
Genome-wide association study implicates immune activation of multiple integrin genes in inflammatory bowel disease
Katrina M. de lange et al.
NATURE GENETICS (2017)
Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease
Nathaniel R. West et al.
NATURE MEDICINE (2017)
Current and emerging therapeutic targets for IBD
Markus F. Neurath
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2017)
Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis
Kim A. Papp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis
William J. Sandborn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Clinical Genomics in Inflammatory Bowel Disease
Holm H. Uhlig et al.
TRENDS IN GENETICS (2017)
Large scale meta-analysis characterizes genetic architecture for common psoriasis associated variants
Lam C. Tsoi et al.
NATURE COMMUNICATIONS (2017)
Gut Microbiome Function Predicts Response to Anti-integrin Biologic Therapy in Inflammatory Bowel Diseases
Ashwin N. Ananthakrishnan et al.
CELL HOST & MICROBE (2017)
Clinical, endoscopic and radiographic outcomes with ustekinumab in medically-refractory Crohn's disease: real world experience from a multicentre cohort
C. Ma et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2017)
Systematic review: predicting and optimising response to anti-TNF therapy in Crohn's disease - algorithm for practical management
N. S. Ding et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2016)
Genetic Markers Predict Primary Non-Response and Durable Response To Anti-TNF Biologic Therapies in Crohn's Disease
Grant E. Barber et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2016)
Stem cell transplantation for tetratricopeptide repeat domain 7A deficiency: long-term follow-up
Jochen Kammermeier et al.
BLOOD (2016)
Association Between Response to Etrolizumab and Expression of Integrin αE and Granzyme A in Colon Biopsies of Patients With Ulcerative Colitis
Gaik W. Tew et al.
GASTROENTEROLOGY (2016)
Patients with Refractory Crohn's Disease Successfully Treated with Ustekinumab
Kimberly A. Harris et al.
INFLAMMATORY BOWEL DISEASES (2016)
mTOR Mediates IL-23 Induction of Neutrophil IL-17 and IL-22 Production
Feidi Chen et al.
JOURNAL OF IMMUNOLOGY (2016)
An essential role for the IL-2 receptor in Treg cell function
Takatoshi Chinen et al.
NATURE IMMUNOLOGY (2016)
Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis
William J. Sandborn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease
B. G. Feagan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Molecular mechanism of action of anti-tumor necrosis factor antibodies in inflammatory bowel diseases
Ulrike Billmeier et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2016)
T-bet is a key modulator of IL-23-driven pathogenic CD4+ T cell responses in the intestine
Thomas Krausgruber et al.
NATURE COMMUNICATIONS (2016)
Predicting durable response or resistance to antitumor necrosis factor therapy in inflammatory bowel disease
Uri Kopylov et al.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2016)
Interleukin 6 Increases Production of Cytokines by Colonic Innate Lymphoid Cells in Mice and Patients With Chronic Intestinal Inflammation
Nick Powell et al.
GASTROENTEROLOGY (2015)
Fecal Microbiota Transplantation Induces Remission in Patients With Active Ulcerative Colitis in a Randomized Controlled Trial
Paul Moayyedi et al.
GASTROENTEROLOGY (2015)
Findings From a Randomized Controlled Trial of Fecal Transplantation for Patients With Ulcerative Colitis
Noortje G. Rossen et al.
GASTROENTEROLOGY (2015)
New Insights into the Mechanisms of Action of Anti-Tumor Necrosis Factor-α Monoclonal Antibodies in Inflammatory Bowel Disease
Stephanie M. Slevin et al.
INFLAMMATORY BOWEL DISEASES (2015)
The biology of innate lymphoid cells
David Artis et al.
NATURE (2015)
Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations
Jimmy Z. Liu et al.
NATURE GENETICS (2015)
The unusual suspects-innate lymphoid cells as novel therapeutic targets in IBD
Rimma Goldberg et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2015)
Patients with LRBA deficiency show CTLA4 loss and immune dysregulation responsive to abatacept therapy
Bernice Lo et al.
SCIENCE (2015)
Environmental risk factors in inflammatory bowel disease: a population-based case-control study in Asia-Pacific
Siew C. Ng et al.
GUT (2015)
Mechanisms of Jak/STAT Signaling in Immunity and Disease
Alejandro V. Villarino et al.
JOURNAL OF IMMUNOLOGY (2015)
Standardized Recording of Parameters Related to the Natural History of Inflammatory Bowel Disease: From Montreal to Paris
Jeffrey S. Hyams
DIGESTIVE DISEASES (2014)
Absence of a role for interleukin-13 in inflammatory bowel disease
Paolo Biancheri et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2014)
Subcutaneous Golimumab Induces Clinical Response and Remission in Patients With Moderate-to-Severe Ulcerative Colitis
William J. Sandborn et al.
GASTROENTEROLOGY (2014)
The Microbiome in Inflammatory Bowel Disease: Current Status and the Future Ahead
Aleksandar D. Kostic et al.
GASTROENTEROLOGY (2014)
The Diagnostic Approach to Monogenic Very Early Onset Inflammatory Bowel Disease
Holm H. Uhlig et al.
GASTROENTEROLOGY (2014)
TTC7A mutations disrupt intestinal epithelial apicobasal polarity
Amelie E. Bigorgne et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Characterization of Innate Lymphoid Cells in Human Skin and Blood Demonstrates Increase of NKp44+ILC3 in Psoriasis
Federica Villanova et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2014)
Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial
Severine Vermeire et al.
LANCET (2014)
In vivo imaging using fluorescent antibodies to tumor necrosis factor predicts therapeutic response in Crohn's disease
Raja Atreya et al.
NATURE MEDICINE (2014)
iPOP Goes the World: Integrated Personalized Omics Profiling and the Road toward Improved Health Care
Jennifer Li-Pock-Than et al.
CHEMISTRY & BIOLOGY (2013)
Neutralization of Membrane TNF, but Not Soluble TNF, Is Crucial for the Treatment of Experimental Colitis
Clementine Perrier et al.
INFLAMMATORY BOWEL DISEASES (2013)
52-Week Efficacy of Adalimumab in Patients with Moderately to Severely Active Ulcerative Colitis Who Failed Corticosteroids and/or Immunosuppressants
Walter Reinisch et al.
INFLAMMATORY BOWEL DISEASES (2013)
Whole-exome sequencing identifies tetratricopeptide repeat domain 7A (TTC7A) mutations for combined immunodeficiency with intestinal atresias
Rui Chen et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2013)
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
Brian G. Feagan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
William J. Sandborn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Involvement of JAK/STAT signaling in the pathogenesis of inflammatory bowel disease
Mehmet Coskun et al.
PHARMACOLOGICAL RESEARCH (2013)
The Age of Gene Discovery in Very Early Onset Inflammatory Bowel Disease
Aleixo M. Muise et al.
GASTROENTEROLOGY (2012)
Loss of Interleukin-10 Signaling and Infantile Inflammatory Bowel Disease: Implications for Diagnosis and Therapy
Daniel Kotlarz et al.
GASTROENTEROLOGY (2012)
Increasing Incidence and Prevalence of the Inflammatory Bowel Diseases With Time, Based on Systematic Review
Natalie A. Molodecky et al.
GASTROENTEROLOGY (2012)
The Transcription Factor T-bet Regulates Intestinal Inflammation Mediated by Interleukin-7 Receptor+ Innate Lymphoid Cells
Nick Powell et al.
IMMUNITY (2012)
JAK and STAT Signaling Molecules in Immunoregulation and Immune-Mediated Disease
John J. O'Shea et al.
IMMUNITY (2012)
Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease
Luke Jostins et al.
NATURE (2012)
The gut microbiota in IBD
Chaysavanh Manichanh et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2012)
Role of the Commensal Microbiota in Normal and Pathogenic Host Immune Responses
Dan R. Littman et al.
CELL HOST & MICROBE (2011)
Recent Insights Into the Genetics of Inflammatory Bowel Disease
Judy H. Cho et al.
GASTROENTEROLOGY (2011)
Antibodies Against Tumor Necrosis Factor (TNF) Induce T-Cell Apoptosis in Patients With Inflammatory Bowel Diseases via TNF Receptor 2 and Intestinal CD14+ Macrophages
Raja Atreya et al.
GASTROENTEROLOGY (2011)
Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial
Walter Reinisch et al.
GUT (2011)
The mucosal addressin cell adhesion molecule antibody PF-00547,659 in ulcerative colitis: a randomised study
Severine Vermeire et al.
GUT (2011)
Interleukin-10 Signaling in Regulatory T Cells Is Required for Suppression of Th17 Cell-Mediated Inflammation
Ashutosh Chaudhry et al.
IMMUNITY (2011)
Crohn's Disease Activity Index Does Not Correlate with Endoscopic Recurrence One Year After Ileocolonic Resection
Miguel Regueiro et al.
INFLAMMATORY BOWEL DISEASES (2011)
IL-23-responsive innate lymphoid cells are increased in inflammatory bowel disease
Alessandra Geremia et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2011)
Intestinal homeostasis and its breakdown in inflammatory bowel disease
Kevin J. Maloy et al.
NATURE (2011)
RNA sequencing: advances, challenges and opportunities
Fatih Ozsolak et al.
NATURE REVIEWS GENETICS (2011)
Inflammatory Skin and Bowel Disease Linked to ADAM17 Deletion
Diana C. Blaydon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Disease Activity, ANCA, and IL23R Genotype Status Determine Early Response to Infliximab in Patients With Ulcerative Colitis
Matthias Juergens et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2010)
Tumour necrosis factor-alpha and interferon-gamma production measured at the single cell level in normal and inflamed human intestine
T. T. MACDONALD et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2010)
Innate lymphoid cells drive interleukin-23-dependent innate intestinal pathology
Sofia Buonocore et al.
NATURE (2010)
Colectomy Rate Comparison After Treatment of Ulcerative Colitis With Placebo or Infliximab
William J. Sandborn et al.
GASTROENTEROLOGY (2009)
Differential regulation of interleukin 17 and interferon γ production in inflammatory bowel disease
L. Rovedatti et al.
GUT (2009)
Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis
I. Arijs et al.
GUT (2009)
The IL-23/Th17 Axis in the Immunopathogenesis of Psoriasis
Antonella Di Cesare et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2009)
Genome-wide scan reveals association of psoriasis with IL-23 and NF-κB pathways
Rajan P. Nair et al.
NATURE GENETICS (2009)
MECHANISMS OF DISEASE Inflammatory Bowel Disease
Clara Abraham et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Inflammatory Bowel Disease and Mutations Affecting the Interleukin-10 Receptor
Erik-Oliver Glocker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Increased Efficacy of Delayed-Release Mesalamine 4.8g/D (800mg Tablet) in Patients Previously Diagnosed with Ulcerative Colitis (UC)
William J. Sandborn et al.
GASTROENTEROLOGY (2009)
The gut microbiota shapes intestinal immune responses during health and disease
June L. Round et al.
NATURE REVIEWS IMMUNOLOGY (2009)
Relationships Between Disease Activity and Serum and Fecal Biomarkers in Patients With Crohn's Disease
Jennifer Jones et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2008)
IL23 differentially regulates the Th1/Th17 balance in ulcerative colitis and Crohn's disease
T. Kobayashi et al.
GUT (2008)
Analysis of bacterial bowel communities of IBD patients: What has it revealed?
Harry Sokol et al.
INFLAMMATORY BOWEL DISEASES (2008)
Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells
Michelle A. Lowes et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2008)
Phenotypic and functional features of human Th17 cells
Francesco Annunziato et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2007)
Certolizumab pegol for the treatment of Crohn's disease
William J. Sandborn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Prediction of antitumour necrosis factor clinical efficacy by real-time visualisation of apoptosis in patients with Crohn's disease
Jan M. H. Van den Brande et al.
GUT (2007)
Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial
Jean-Frederic Colombel et al.
GASTROENTEROLOGY (2007)
Polymorphism in IgG Fc receptor gene FCGR3A and response to infliximab in Crohn's disease: a subanalysis of the ACCENT I study
Edouard I. Louis et al.
PHARMACOGENETICS AND GENOMICS (2006)
A genome-wide association study identifies IL23R as an inflammatory bowel disease gene
Richard H. Duerr et al.
SCIENCE (2006)
Interleukin-23 drives innate and T cell-mediated intestinal inflammation
Sophie Hue et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2006)
Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides
Spencer C. Liang et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2006)
Differential activity of IL-12 and IL-23 in mucosal and systemic innate immune pathology
Holm H. Uhlig et al.
IMMUNITY (2006)
Onercept for moderate-to-severe Crohn's disease: A randomized, double-blind, placebo-controlled trial
Paul Rutgeerts et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2006)
Anti-IL-23 therapy inhibits multiple inflammatory pathways and ameliorates autoimmune encephalomyelitis
Y Chen et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
Angiogenesis as a novel component of inflammatory bowel disease pathogenesis
Silvio Danese et al.
GASTROENTEROLOGY (2006)
Infliximab for induction and maintenance therapy for ulcerative colitis
P Rutgeerts et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn's disease
T Hlavaty et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2005)
IBD5 polymorphisms in inflammatory bowel disease: Association with response to infliximab
Elena Urcelay et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2005)
Children with early-onset inflammatory bowel disease (IBD): Analysis of a pediatric IBD Consortium Registry
MB Heyman et al.
JOURNAL OF PEDIATRICS (2005)
Detection and characterization of OX40 ligand expression in human airway smooth muscle cells: A possible role in asthma?
JK Burgess et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2004)
Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn's disease
E Louis et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2004)
Transmembrane tumor necrosis factor is a potent inducer of colitis even in the absence of its secreted form
N Corazza et al.
GASTROENTEROLOGY (2004)
Tumour necrosis factor-α receptor 1 and 2 polymorphisms in inflammatory bowel disease and their association with response to infliximab
M Pierik et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2004)
Anti-interleukin-12 antibody for active Crohn's disease
PJ Mannon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
The Janus kinases (Jaks)
K Yamaoka et al.
GENOME BIOLOGY (2004)
Reduction in diversity of the colonic mucosa associated bacterial microflora in patients with active inflammatory bowel disease
SJ Ott et al.
GUT (2004)
Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease
JMH Van Den Brande et al.
GASTROENTEROLOGY (2003)
Tumor necrosis factor signaling
H Wajant et al.
CELL DEATH AND DIFFERENTIATION (2003)
Response to infliximab treatment in Crohn's disease is not associated with mutations in the CARD15 (NOD2) gene:: an analysis in 534 patients from two multicenter, prospective GCP-level trials
S Mascheretti et al.
PHARMACOGENETICS (2002)
NOD2/CARD15 does not influence response to infliximab in Crohn's disease
S Vermeire et al.
GASTROENTEROLOGY (2002)
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
SB Hanauer et al.
LANCET (2002)
The contribution of NOD2 gene mutations to the risk and site of disease in inflammatory bowel disease
AP Cuthbert et al.
GASTROENTEROLOGY (2002)
Interleukin-1 beta and tumor necrosis factor-alpha induce chemokine and matrix metalloproteinase gene expression in human colonic subepithelial myofibroblasts
T Okuno et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2002)
Etanercept for active Crohn's disease: A randomized, double-blind, placebo-controlled trial
WJ Sandborn et al.
GASTROENTEROLOGY (2001)
Reverse signaling through transmembrane TNF confers resistance to lipopolysaccharide in human monocytes and macrophages
G Eissner et al.
JOURNAL OF IMMUNOLOGY (2000)
分享论文
